
# RESEARCH

**Open Access** 





Xue Pan<sup>1</sup>, Xinyue Zhang<sup>1</sup>, Xinyi Wu<sup>1</sup>, Yue Zhao<sup>1</sup>, Yilong Li<sup>1</sup>, Zitong Chen<sup>1</sup>, Yue Hu<sup>1</sup> and Xuezhao Cao<sup>1\*</sup>

# Abstract

**Background** Obstructive Sleep Apnea (OSA) is a widespread sleep disturbance linked to metabolic and cardiovascular conditions. The Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratios (NHHR) has been proposed as being a potential biomarker to gauge cardiovascular risk. However, its relationship with OSA remains unclear.

**Methods** This survey investigated the link NHHR to OSA in American citizens aged 20 and older using information collected via the National Health and Nutrition Examination Survey (NHANES) during the years 2017 to 2020. Logistic regression models with multivariable adjustments were employed to assess this relationship. Nonlinear associations were explored using smooth curve fitting, with a two-part linear regression model identifying a threshold effect. Subgroup analyses were conducted to evaluate population-specific differences.

**Results** The survey encompassed 6763 participants, with an average age of 50.75 ± 17.32. The average NHHR stood at 2.74, accompanied by a standard deviation of 1.34, while the average frequency of OSA was 49.93%. Upon adjusting for covariates, each unit increase in NHHR may be associated with a 9% rise in OSA incidence. (95% confidence intervals 1.04–1.14; *P* < 0.0001). Notably, a U-shaped curve depicted the NHHR-OSA relationship, with an inflection point at 4.12. Subgroup analyses revealed consistent associations, with educational attainment and diabetes status modifying the NHHR-OSA relationship.

**Conclusion** The study highlights NHHR as a potential tool for OSA prediction, presenting avenues for advanced risk evaluation, tailored interventions, personalized treatment approaches, and preventive healthcare.

Keywords NHHR, NHANES, Obesity, Obstructive sleep apnea

\*Correspondence: Xuezhao Cao xzcao@cmu.edu.cn <sup>1</sup>Department of Anesthesiology, the First Hospital of China Medical University, Shenyang, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicate of the original autory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

# Introduction

Obstructive Sleep Apnea (OSA) is a prevalent sleep disorder characterized by recurrent episodes of upper airway obstruction during sleep, leading to sporadic hypoxemia and recurrent awakenings. In the United States (US), it affects roughly 17% of women and 34% of men aged 30 and 70 [1]. Symptoms of OSA include excessive daily sleepiness, neurocognitive impairment [2], diminished quantity of life, as well as endocrine, metabolic [3], and cardiovascular-related changes. Left untreated, OSA can precipitate serious health complications, including high blood pressure, cardiovascular diseases [4], metabolic syndrome [5] and diabetes [6]. Crucially, OSA has a significant relationship with changes in metabolism and is recognized as an independent risk factor for cardiovascular ailments. Therefore, there is an imperative to identify novel and more precise biomarkers for predicting the probability of adverse cardiovascular events in individuals afflicted by OSA.

Numerous studies have investigated the intricate connection between lipid abnormalities and OSA. For instance, a prospective cohort study involving 846 older adults demonstrated a robust association between highdensity lipoprotein cholesterol (HDL-C) and severe OSA, while low-density lipoprotein (LDL) did not exhibit an independent association [7]. Similarly, a retrospective analysis of 2361 people revealed that, in comparison to controls, those with OSA had increased triglycerides, greater Non-High-Density Lipoprotein Cholesterol (NHDL-C) and lower HDL-C. Moreover, a significant link was observed with the severity of OSA of HDL-C [8]. Furthermore, individuals diagnosed with OSA exhibit notably increased levels of oxidized low-density lipoprotein (oxLDL), a factor associated with preclinical atherosclerosis [9]. HDL-C ameliorates the inhibitory effect of oxLDL on vascular reactivity [10].

The NHHR, integrating features of both HDL-C and non-HDL-C, has been recognized as a comprehensive marker for evaluating atherosclerosis. Previous research has demonstrated its superior predictive and diagnostic efficacy in assessing the risk of atherosclerosis [11], diabetes type 2 [12], and metabolism syndrome [13] compared to traditional lipid indicators. Furthermore, recent research has emphasized the linkage and prognostic worth of NHHR with different illnesses, including depression [14], kidney stones [15], and suicidal ideation [16]. Exploring the relationship between NHHR and OSA could yield valuable insights into the interconnectedness of lipid metabolism and sleep quality, potentially informing preventive and therapeutic strategies for these conditions.

The complexity of OSA and its implications for cardiovascular risk underscores the importance of identifying reliable biomarkers. Given this context, delving into the correlation between NHHR and OSA could unveil a simple yet effective tool for predicting OSA risk. Therefore, this study endeavors to explore the relationship between NHHR and OSA risk in the adult population. By elucidating this intricate connection, this study contributes to the existing knowledge by proposing NHHR as a comprehensive biomarker for evaluating OSA risk, offering advantages over traditional lipid parameters, such as HDL-C and LDL-C. The gleaned observations could pave the way for personalized management strategies and interventions to mitigate the adverse health outcomes associated with OSA.

# Methodology

#### Study design and population

This snapshot survey examines the link to NHHR and OSA, utilizing the data provided from the NHANES during the years 2017 to 2020. NHANES offers a comprehensive and accurate representation of the whole US population, providing in-depth information on health, nutrition, and demographic characteristics. The NHANES survey methodology involves a complex, multi-stage, probability-cluster sampling technique. Additional details regarding NHANES can be available on the webpage www.cdc.gov/nchs/Nhanes/. The entire NHANES participants provided informed signed agreement, and it obtained approval from the Research Ethics Committee of the National Centre for Health Statistics. The initial sample consisted of 15,560 individuals with valid NHANES data from 2017 to 2020. Exclusion criteria included individuals under 20 years old, those with missing NHHR or OSA data, and those with missing covariate data. The flowchart in Fig. 1 illustrates the specific selection process.

#### Calculation of NHHR Index

The NHHR index was computed using the following calculation: (Total Cholesterol (TC) - HDL-C) split by HDL-C.

## **Diagnosis of OSA**

High-risk for OSA was defined based on participant responses to three binary questions in NHANES: (1) Suffering chronic extreme daytime sleepiness, even after getting around 7 h or more of sleep per night on weekdays or workdays, happening 16–30 times each month; (2) Reporting breathing pauses, snorting, or gasping for air on 3 or more nights per week; (3) Loud snoring on 3 or more nights per week [17].

## Covariates

A multivariable-adjusted model was employed to summarize variables potentially influencing NHHR index and OSA correlation. Covariates considered in this study




Fig. 1 Flowchart of participant selection. HDL, High-Density Lipoprotein Cholesterol; TC, Total Cholesterol

included various demographic and health-related factors, as outlined in Table 1 [17]. Detailed information regarding the measuring techniques for these variables is available on the official Centers for Disease Control and Prevention website at www.cdc.gov/nchs/nhanes/.

#### Statistical analysis

The analytical methods were implemented with R 4.0.5 software and Empowerstats 2.0, taking into consideration the intricate NHANES sampling design with sample visit weights. Descriptive analyses were conducted, reporting proportion adjusted for weights (%) of qualitative parameters and weighted averages with corresponding statistical dispersion pertaining to quantitative data. Qualitative parameters were assessed using chi-square tests, while

quantitative data were investigated using analysis of variance (ANOVA).

Multivariable Logit models (Model I, II, and III) were developed to determine the odds ratio (OR) and 95% confidence intervals (CI) for the association between the NHHR index and OSA. Model I was unadjusted for covariates. Model II was adjusted for race, sex and age. Model III additionally included modifications for relationship situation, educational attainment, physical activity, BMI, smoking habits, drinking habits, high blood pressure, diabetes, and previous cardiovascular events.

Subgroup analyses and interaction tests were conducted to explore potential differences among the different populations. The study investigated the presence of nonlinear relationships between OSA and NHHR index by employing smooth curve fitting. Threshold

Covariate	Description
Age	Continuous variable representing age in years.
Sex	Categorized as male or female.
Race	Participant's racial background.
Education level	Categorized as lower than high school, high school or equivalent, college or above.
Marital status	Categorized as married/cohabiting, widowed/divorced/separated, never married.
Physical activity	Categorized based on physical activity level.
BMI	Continuous measure of body mass index.
Smoking status	Categorized as < 100 cigarettes, never smoker; > 100 cigarettes, currently not
Alcohol	smoking. former smoker: > 100 cigarettes. currently smoking. current smoker. Categorized based on whether alcohol is consumed at least once a month.
Hypertension	Defined as systolic blood pressure > 130 mmHg and/or diastolic blood pressure > 80
	mmHg.
Diabetes	Defined as self-reported diabetes, $HbA1c > 6.5\%$ , or fasting blood glucose >
	11.1mmol/L.
CVD	History of cardiovascular disease based on self-reported doctor diagnosis obtained
	during interviews.

Table 1 Covariates along with their descriptions or categorizations. Covariates included in this study. BMI, Body Mass Index; CVD, Cardiovascular Disease

relationships were investigated using a two-part linear regression. The predictive capacity of NHHR, HDL-C, and TC for the incidence of OSA was evaluated using Receiver Operating Characteristic (ROC) curves and Area Under the Curve (AUC). A *P*-value less than 0.05 was considered statistically significant for all results.

## Results

## **Baseline characteristics of participants**

The paper's survey comprised 6,763 participants, with an average age of  $50.75\pm17.32$  years. The sample consisted of 48.38% males and 51.62% females. Table 2 presents the weighted baseline traits. The mean NHHR index was  $2.74\pm1.34$ . NHHR quartile ranges were defined as follows: Quartile 1 included values less than or equal to 1.82, Quartile 2 encompassed values between 1.82 and 2.50, Quartile 3 ranged between 2.51 and 3.38, and Quartile 4 comprised values greater than 3.38. The prevalence of OSA was 49.93% among participants. Quartile 4 of NHHR, when compared to Quartile 1, exhibited likelihoods with older age, a greater percentage of males, lower levels of education, higher BMI, increased rates of smoking, elevated rates of high blood pressure and diabetes, lower HDL-C, and higher TC.

## Association between NHHR Index and OSA Risk

After adjusting for all relevant factors, each additional unit of NHHR showed a 9% positive correlation with the occurrence of OSA (OR=1.09; 95% CI 1.04–1.14; P<0.01). This indicates a strong positive association between NHHR and OSA. Furthermore, analysis of NHHR in quartiles revealed that Quartile 4 had a 38%

higher likelihood of OSA compared to Quartile 1 (OR=1.38; 95% CI 1.19–1.61; P<0.01) (Table 3).

In the analysis, NHHR was examined as a continuous variable and a categorical variable in quartiles.

Model I, no covariates were adjusted. Model II, Age, Gender, and Race were adjusted. Model III, Age, Gender, Race, Marital status, Education level, Physical activity, BMI, Smoke status, Alcohol, Hypertension, Diabetes, and History of cardiovascular disease. OR, Odds Ratio; CI, Confidence Intervals; OSA, Obstructive Sleep Apnea; NHHR, Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio; Ref, Reference.

## Analysis of curve fitting and threshold effects

Model III revealed an inverted U-shaped relationship between NHHR index and OSA prevalence (Fig. 2). Further analysis of threshold effects revealed a curve inflection point at 4.12. When NHHR falls below this threshold, each additional unit increase is associated with a 16% higher risk of OSA (OR=1.16; 95% CI 1.09–1.23; P<0.0001). However, values above 4.12 did not yield significant results in their relationship (OR=0.98; 95% CI 0.91–1.06; P=0.5986), as indicated by a P-value of 0.004 from the likelihood ratio test (Table 4).

# **Subgroup Analysis**

Multi-subgroup analyses and interaction tests, based on various covariates, were conducted to assess the strength of the NHHR-OSA relationship and identify potential population differences (Table 5). In most subgroups, a consistent association between NHHR and OSA was

Variables	Quartiles of NHHR				P-Value
o, see-o-defectes initial fue	Q1	Q2	Q3	Q4	Ner an Tabardanak
Age(year)	$47.53 \pm 19.29$	$49.04 \pm 17.93$	$49.93 \pm 16.46$	$47.26 \pm 15.28$	0.0118
BMI(kg/m <sup>2</sup> )	$26.61\pm7.14$	$29.28 \pm 7.29$	$30.83 \pm 7.25$	$32.42\pm 6.84$	< 0.0001
HDL(mmol/L)	$1.79 \pm 0.44$	$1.48 \pm 0.28$	$1.25 \pm 0.23$	$1.05 \pm 0.21$	< 0.0001
TC(mmol/L)	$4.25 \pm 0.92$	$4.66 \pm 0.88$	$4.88 \pm 0.89$	$5.61 \pm 1.06$	< 0.0001
Gender(%)					< 0.0001
male	34.84	42.07	52.46	65.80	
female	65.16	57.93	47.54	34.20	
Race(%)					< 0.0001
Mexican American	6.28	6.97	8.62	9.95	
Other Hispanic	6.10	7.12	7.06	8.92	
Non-Hispanic white	66.56	66.51	65.14	63.16	
Non-Hispanic black	13.66	10.97	8.92	7.34	
Other races	7.41	8.43	10.26	10.63	
Educational level (%)					< 0.0001
Under high school	7.10	9.07	10.64	12.56	0.0001
High school or	25.36	23.80	29.34	30.03	
equivalent	20.00	20.00	<i>27.5</i> 1	20.02	
Above high school	67.54	67.13	60.02	57.40	
Marital status (%)	07.51	07.15	00.02	57.10	< 0.0001
Married	58.79	59.76	64.50	68.29	-0.0001
Single	17.35	21.05	19.82	15.38	
with partner	23.86	19.19	15.69	16.33	
Smoking status(%)	23.80	19.19	15.09	10.55	0.0006
Never smoker	60.64	57.97	58.01	51.61	0.0000
Former smoker	23.85	27.31	22.82	30.56	
Current smoker $A \log \log \log 1/(9/2)$	15.51	14.72	19.17	17.82	<0.0001
Alcohol(%)	04.00	04.65	00.04	04.02	< 0.0001
Drinks	94.99	94.65	90.94	94.03	
Never	5.01	5.35	9.06	5.97	.0.0001
Diabetes(%)	11.42	11.70	15.50	17 (0	< 0.0001
Yes	11.43	11.79	15.50	17.60	
No	88.57	88.21	84.50	82.40	0.0001
Hypertension(%)					< 0.0001
Yes	32.40	35.37	38.85	44.98	
No	67.60	64.63	61.15	55.02	
Physical activity(%)					0.7107
No physical activity	42.78	45.29	43.21	44.65	
Physical activity	57.22	54.71	56.79	55.35	
CVD(%)					0.7415
Yes	10.61	9.35	9.37	8.89	
No	89.39	90.65	90.63	91.11	
OSA(%)					< 0.0001
Yes	38.14	44.38	51.63	59.62	
No	61.86	55.62	48.37	40.38	

 Table 2
 Baseline characteristics of participants in the NHANES 2017–2020. Categorized according to NHHR quartiles. NHHR, Non-high-density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio; BMI, body Mass Index; HDL, High-Density Lipoprotein Cholesterol; TC, total cholesterol; CVD, Cardiovascular Disease; OSA, Obstructive Sleep Apnea

3		OR (95% CI), P-val	ue
	Model I	Model II	Model III
OSA			
NHHR	1.22 (1.18, 1.27) <0.0001	1.21 (1.16, 1.26) <0.0001	1.09 (1.04, 1.14) < 0.0001
Catagories			
quartile1	Ref	Ref	Ref
quartile2	1.25 (1.09, 1.43) 0.0014	1.21 (1.06, 1.39) 0.0056	1.05 (0.91, 1.21) 0.4881
quartile3	1.61 (1.40, 1.84) <0.0001	1.54 (1.34, 1.77) <0.0001	1.19 (1.03, 1.38) 0.0194
quartile4	2.07 (1.80, 2.37) <0.0001	1.96 (1.70, 2.26) <0.0001	1.38 (1.19, 1.61) <0.0001

Table 3 Multivariable logistic regression models for the association between NHHR and OSA




Fig. 2 Smoothed curve fit between NHHR and OSA The blue bars show the fitted 95% confidence intervals (95% CI) and the fitted smoothed curves are shown in red. OSA, Obstructive Sleep Apnea; NHHR, Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio

observed. However, educational attainment was found to modify this association (*P* for interaction=0.0016). Furthermore, differences were noted among diabetic populations (*P* for interaction=0.0129), with a stronger NHHR-OSA association observed in non-diabetic individuals (OR=1.11; 95% CI 1.05–1.16; P<0.0001), compared to diabetic patients (OR=0.98; 95% CI 0.91–1.06; *P*=0.6789).

# **ROC curve analysis**

ROC curve analysis indicated that NHHR exhibited slightly higher specificity compared to HDL-C and TC,

	OR (95% CI), <i>P</i> -value
Fitting by the standard linear model	1.09 (1.04, 1.14) < 0.0001
Fitting by the two-piecewise linear model	
Inflection point	4.12
NHHR<4.12	1.16 (1.09, 1.23) < 0.0001
NHHR>4.12	0.98 (0.91, 1.06) 0.5986
P for log-likelihood ratio	0.004

 Table 4
 The threshold effect analysis of the NHHR on OSA risk. OR, odds ratio; CI, confidence intervals; NHHR, Non-high-density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio; OSA, Obstructive Sleep Apnea

with a specificity of 0.5839 and sensitivity of 0.5434 (Fig. 3).

#### Discussion

This cross-sectional research encompassed a representative sample of 6,763 American citizens aged 20 and older from the NHANES dataset. The analysis revealed an essential connection between NHHR and the likelihood of OSA. This robust association persisted even following adjusting for various covariates, suggesting that NHHR could serve as a reliable tool for assessing the risk of OSA. The subgroup analysis revealed that individuals with educational attainment levels below high school or above college should pay particular attention to managing NNHR. Notably, these findings revealed a nonlinear pattern, with a critical threshold identified at an NHHR of 4.12, beyond which the association with OSA risk diminished. These results underscore the clinical relevance of maintaining an optimal NHHR level to potentially mitigate the risk of OSA.

The findings contribute to the expanding body of evidence linking lipid abnormalities, specifically NHHR, to the risk of developing OSA. Previous investigations have primarily focused on the roles of HDL-C and TC concerning OSA. The Sleep Heart Health Study research group conducted a prospective cohort study that identified a robust association between HDL-C levels and the severity of sleep-disordered breathing [18]. Similarly, a recent case-control study involving 1,310 children observed lower HDL-C levels and higher TC in OSA patients [19]. Animal models have also suggested that intermittent hypoxia characteristic of OSA may increase HDL-C expression, potentially through the upregulation of the HDL-C receptor SRB1 [20]. These studies indirectly support the findings, indicating a complex interplay between lipid metabolism and OSA pathogenesis.

However, conflicting results have emerged from various studies, highlighting the need for further investigation. For instance, a cross-sectional study involving 753 Australian men revealed no significant correlation between OSA and HDL-C levels [21]. Furthermore, a Mendelian randomization (MR) investigation revealed no clear correlation between HDL-C and OSA [22]. These discrepancies may arise from variations in study populations, ethnicities, and OSA assessment criteria. Thus, this study aimed to introduce NHHR as a novel atherosclerosis indicator, potentially enhancing the predictive ability of HDL-C and non-HDL-C for OSA risk.

The connection regarding NHHR and OSA incidence can be explained by various mechanisms incurred by lipid metabolism. Dysfunctional HDL-C, particularly its subfractions HDL1-3, is implicated in atherosclerosis [23]. HDL-C's anti-inflammatory, antioxidant, and antiatherosclerotic properties are crucial in this context [24]. HDL-C enhances endothelial function through various mechanisms, including raising intracellular Ca<sup>2+</sup> levels, activating Akt to trigger the release of nitric oxide, and increasing the expression of endothelial nitric oxide synthase (eNOS) via lysophospholipids, such as sphingosylphosphorylcholine (SPC), sphingosine-1phosphate (S1P), and lysosulfatide (LSF) [25, 26]. Additionally, HDL enhances the expression of eNOS by interacting with SRB1 receptors present on endothelial cells [27]. Dysfunctional HDL-C may also contribute to increased levels of oxLDL, promoting inflammation and atherosclerosis [28].

The clinical relevance of this study lies in its identification of NHHR as a potential biomarker for predicting OSA risk in adults. This finding has direct implications for patient care across several domains: (1) Enhanced Risk Assessment: NHHR demonstrates advantages over traditional lipid parameters in predicting OSA risk. Integrating NHHR measurements into routine assessments enables clinicians to more accurately identify individuals prone to OSA development. (2) Targeted Interventions: Recognizing NHHR as a predictive biomarker for OSA enables healthcare providers to implement focused interventions aimed at managing lipid irregularities to mitigate OSA risk. These interventions may involve tailored lifestyle modifications, pharmacotherapy, or other targeted approaches based on individual patient profiles. (3) Personalized Management Strategies: Understanding NHHR's role in OSA pathophysiology opens avenues for personalized management strategies. Clinicians can

Subgroup Analysis	OSA,OR(95%CI),P-value	<i>P</i> for interaction
Age(year)		0.2170
<=40	1.08 (1.01, 1.17) 0.0356	
>40, <=60	1.12 (1.04, 1.20) 0.0031	
>60	1.02 (0.94, 1.10) 0.6481	
Gender(%)		0.4084
male	1.05 (0.99, 1.11) 0.0840	
female	1.09 (1.02, 1.16) 0.0142	
Race(%)		0.2870
Mexican American	1.13 (1.00, 1.28) 0.0561	
Other Hispanic	1.02 (0.93, 1.11) 0.7280	
Non-Hispanic white	1.05 (0.98, 1.13) 0.1445	
Non-Hispanic black	1.16 (1.06, 1.28) 0.0018	
Other races	1.09 (0.98, 1.22) 0.1279	
Educational level (%)		0.0016
Under high school	1.18 (1.07, 1.30) 0.0008	
High school or	0.98 (0.92, 1.05) 0.5536	
equivalent		
Above high school	1.11 (1.05, 1.18) 0.0002	
Marital status (%)		0.3965
Married	1.09 (1.03, 1.15) 0.0017	
Single	1.02 (0.93, 1.11) 0.7387	
with partner	1.09 (0.98, 1.22) 0.1091	
Smoking status(%)		0.4278
Never smoker	1.10 (1.04, 1.16) 0.0017	
Former smoker	1.08 (0.99, 1.17) 0.0939	
Current smoker	1.02 (0.94, 1.12) 0.6283	
Alcohol(%)		0.0002
Drinks	1.06 (1.01, 1.10) 0.0116	
Never	1.45 (1.23, 1.71) < 0.0001	
$BMI(kg/m^2)$		0.8383
<=25	1.04 (0.93, 1.16) 0.4780	
>25, <=30	1.05 (0.98, 1.13) 0.1595	
>30	1.07 (1.01, 1.14) 0.0196	
Diabetes(%)		0.0129
Yes	0.98 (0.91, 1.06) 0.6789	
No	1.11 (1.05, 1.16) < 0.0001	
Hypertension(%)		0.3982
Yes	1.10 (1.03, 1.16) 0.0026	
No	1.06 (1.00, 1.12) 0.0482	
Physical activity(%)		0.3304
No physical activity	1.05 (0.99, 1.12) 0.0871	
Physical activity	1.10 (1.04, 1.16) 0.0012	
CVD(%)		0.3500
Yes	1.01 (0.89, 1.15) 0.8176	
No	1.08 (1.03, 1.13) 0.0006	

**Table 5** Stratified analysis of the correlation between NHHR and OSA. Stratification of covariates adjusted according to model III. OR, odds ratio; CI, confidence intervals; OSA, Obstructive Sleep Apnea; BMI, body Mass Index; CVD, Cardiovascular Disease; NHHR, Non-high-density Lipoprotein Cholesterol to high-density lipoprotein cholesterol ratio




Fig. 3 ROC curve between OSA and NHHR. ROC, Receiver Operating Characteristic; OSA, Obstructive Sleep Apnea; NHHR, Non-High-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio; HDL, High-Density Lipoprotein Cholesterol; TC, Total Cholesterol

utilize NHHR measurements to customize treatment plans and interventions for patients with OSA, potentially leading to improved outcomes and enhanced patient care. (4) Preventive Medicine: NHHR may help predict the occurrence of OSA, allowing for preventive measures to be initiated before significant symptoms or complications emerge. Early identification and intervention hold the potential to prevent or delay OSA progression and its associated cardiovascular risks, promoting overall health and well-being.

# Study strengths and limitations

The conclusion drawn from this study is robust, as it involved a large and geographically representative group of US adults from NHANES, with comprehensive adjustments made for covariates. However, certain limitations should be acknowledged. The nature of this snapshot survey investigation precludes the establishment of a direct causal link between NHHR and OSA, and the potential for reverse causality cannot be entirely ruled out. Additionally, the cholesterol data utilized were obtained from fasting samples, which may differ from non-fasting levels. Objective indicators for OSA evaluation were limited, and the study did not extend to investigating NHHR and OSA in children.

#### Conclusion

In conclusion, this study highlights the importance of NHHR as a predictive biomarker for OSA, offering opportunities for enhanced risk assessment, targeted interventions, personalized management strategies, and preventive medicine. Integration of NHHR assessments into clinical routines enables healthcare professionals to enhance patient care by identifying those susceptible to OSA and initiating proactive measures to.

alleviate this risk, consequently enhancing overall health outcomes.

#### Abbreviations

NHDL-C HDL-C	Non-high-density lipoprotein cholesterol High-density lipoprotein cholesterol
LDL	low-density lipoprotein
oxLDL	oxidized low-density lipoprotein
TC	Total Cholesterol
NHHR	NHDL-C and HDL-C ratio
OSA	Obstructive Sleep Apnea
NHANES	National Health and Nutrition Examination Survey
BMI	Body mass index
CVD	Cardiovascular Disease

## **Supplementary Information**

The online version contains supplementary material available at https://doi. org/10.1186/s12944-024-02195-w.

Supplementary Material 1

#### Acknowledgements

Appreciation of individuals or organizations that have helped or supported us!

#### Author contributions

XP, XZ, and XC equally contributed to the conceptualization and design of the study. XP conducted research and drafted the manuscript. XZ and XW participated in data collection and analysis. YZ and YL performed statistical analysis. XP, ZC, and YH drafted the initial manuscript. XC reviewed and revised subsequent drafts of the manuscript. All authors critically reviewed and approved the final manuscript, agreeing to take full responsibility for the integrity and accuracy of the work. All authors contributed to the article and approved the submitted version.

#### Funding

This work was funded by National Natural Science Foundation of China (No. 81300938).

#### Data availability

Data supporting the findings of this study are available within the manuscript .

#### Declarations

#### **Competing interests**

The authors declare no competing interests.

Received: 3 May 2024 / Accepted: 19 June 2024

Published online: 04 July 2024

#### References

- Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177:1006–14.
- Lal C, Ayappa I, Ayas N, Beaudin AE, Hoyos C, Kushida CA, Kaminska M, Mullins A, Naismith SL, Osorio RS, et al. The link between obstructive sleep apnea and neurocognitive impairment an official American thoracic Society Workshop Report. Annals Am Thorac Soc. 2022;19:1245–56.
- Liu PY, Reddy RT. Sleep, testosterone and cortisol balance, and ageing men. Reviews Endocr Metabolic Disorders. 2022;23:1323–39.
- Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, Malhotra A, Martinez-Garcia MA, Mehra R, Pack AI, et al. Sleep apnea: types, mechanisms, and Clinical Cardiovascular consequences. J Am Coll Cardiol. 2017;69:841–58.
- Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol. 2013;62:569–76.
- Al-Jahdali H, Ahmed AE, Abdullah AH, Ayaz K, Ahmed A, Majed A, Sami A, Amirah A, Bassam D. Comorbidities in clinical and polysomnographic features of obstructive sleep apnea: a single Tertiary Care Center Experience. J Epidemiol Glob Health. 2022;12:486–95.
- Roche F, Sforza E, Pichot V, Maudoux D, Garcin A, Celle S, Picard-Kossovsky M, Gaspoz JM, Barthélémy JC, Grp PS. Obstructive sleep apnoea/hypopnea influences high-density lipoprotein cholesterol in the elderly. Sleep Med. 2009;10:882–6.
- Basoglu OK, Tasbakan MS, Kayikcioglu M. Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea? Sleep Med. 2021;88:29–35.
- Díaz-García E, Sanz-Rubio D, García-Tovar S, Alfaro E, Cubero P, Gil AV, Marin JM, Cubillos-Zapta C, García-Río F. Inflammasome activation mediated by oxidised low-density lipoprotein in patients with sleep apnoea and early subclinical atherosclerosis. Eur Respir J. 2023;61:12.

- Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002;161:1–16.
- Iannuzzi A, Giallauria F, Gentile M, Rubba P, Covetti G, Bresciani A, Aliberti E, Cuomo G, Panico C, Tripaldella M, et al. Association between Non-HDL-C/ HDL-C ratio and carotid intima-media thickness in Post-menopausal Women. J Clin Med. 2022;11:9.
- Han MH, Li QM, Qie RR, Guo CM, Zhou QG, Tian G, Huang SB, Wu XY, Ren YC, Zhao Y, et al. Association of non-HDL-C/HDL-C ratio and its dynamic changes with incident type 2 diabetes mellitus: the rural Chinese cohort study. J Diabetes Complicat. 2020;34:6.
- Kim SW, Jee JH, Kim HJ, Jin SM, Suh S, Bae JC, Kim SW, Chung JH, Min YK, Lee MS, et al. Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1. Int J Cardiol. 2013;168:2678–83.
- Qi XY, Wang SJ, Huang QW, Chen XB, Qiu LX, Ouyang KF, Chen YJ. The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and risk of depression among US adults: a cross-sectional NHANES study. J Affect Disord. 2024;344:451–7.
- Hong HJ, He YJ, Gong ZQ, Feng JL, Qu YL. The association between nonhigh-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and kidney stones: a cross-sectional study. Lipids Health Dis. 2024;23:9.
- Qing GW, Deng WP, Zhou YX, Zheng LY, Wang YL, Wei B. The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and suicidal ideation in adults: a populationbased study in the United States. Lipids Health Dis. 2024;23:10.
- 17. Scinicariello F, Buser MC, Feroe AG, Attanasio R. Antimony and sleep-related disorders: NHANES 2005–2008. Environ Res. 2017;156:247–52.
- Newman AB, Nieto FJ, Guidry U, Lind BK, Redline S, Shahar E, Pickering TG, Quan SF. Sleep Heart Hlth Study Res G: relation of sleep-disordered breathing to cardiovascular disease risk factors - the Sleep Heart Health Study. Am J Epidemiol. 2001;154:50–9.
- Lei L, Zhang XY, Wang BB, Lei F, Dai L, Sun XR, Zhao Y, Zhu P, Zou J. Effects of sleep-disordered breathing on serum lipid levels in children:a case control study. BMC Pediatr. 2024;24:6.
- Li JG, Thorne LN, Punjabi NM, Sun CK, Schwartz AR, Smith PL, Marino RL, Rodriguez A, Hubbard WC, O'Donnell CP, Polotsky VY. Intermittent hypoxia induces hyperlipidemia in lean mice. Circul Res. 2005;97:698–706.
- Guscoth LB, Appleton SL, Martin SA, Adams RJ, Melaku YA, Wittert GA. The Association of Obstructive Sleep Apnea and Nocturnal Hypoxemia with lipid profiles in a Population-based study of Community-Dwelling Australian men. Nat Sci Sleep. 2021;13:1771–82.
- Li Y, Miao YY, Tan J, Zhang Q. Association of modifiable risk factors with obstructive sleep apnea: a mendelian randomization study. Aging-Us. 2023;15:14039–65.
- Kollar B, Siarnik P, Hluchanova A, Klobucnikova K, Mucska I, Turcani P, Paduchova Z, Katrencikova B, Janubova M, Konarikova K, et al. The impact of sleep apnea syndrome on the altered lipid metabolism and the redox balance. Lipids Health Dis. 2021;20:8.
- 24. Nicholls SJ, Nelson AJ. HDL and cardiovascular disease. Pathology. 2019;51:142–7.
- Ksiazek M, Chacinska M, Chabowski A, Baranowski M. Sources, metabolism, and regulation of circulating sphingosine-1-phosphate. J Lipid Res. 2015;56:1271–81.
- Nofer JR, van der Giet M, Tölle M, Wolinska I, Lipinski KVW, Baba HA, Tietge UJ, Gödecke A, Ishii I, Kleuser B, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P < sub > 3. J Clin Invest. 2004;113:569–81.
- Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Marcel YL, Anderson RGW, Mendelsohn ME, Hobbs HH, Shaul PW. High-density lipoprotein binding to scavenger receptor-Bl activates endothelial nitric oxide synthase. Nat Med. 2001;7:853–7.
- Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. Faseb J. 2001;15:2073–84.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.